Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
What is your preferred duration of aggrastat therapy, and does it differ if patient presented with NSTEMI versus STEMI?
Related Questions
What has been your approach to percutaneous intervention for calcified nodules and threshold for intervention?
Would you defer or opt for plavix loading during PCI in a patient already on DAPT presenting with NSTEMI attributed to non-ischemic myocardial injury but with known CAD?
Do you recommend routine use of protamine for hemostasis at the end of a transfemoral TAVI?
What has been your approach to minimizing the risk of vascular complications when placing Impella support devices?
Do you prefer the routine use of bivalirudin over UFH during PCI cases in patients presenting with ACS?
What is your preferred duration for triple therapy post-PCI in patients on systemic anticoagulation?
What advice would you give to patients with refractory nausea and vomiting at home who are unable to take oral medications but have recently had a PCI and stent placement requiring uninterrupted DAPT?
Do you avoid high-potency P2Y12 inhibitors in favor of clopidogrel in patients with atrial fibrillation on a DOAC who undergo PCI?
What is a reasonable timeline for a left heart catheterization in a patient with newly diagnosed severe LV systolic dysfunction of unclear etiology and without an ACS presentation?
What type of DES should you opt for if a patient has or is concerned about possible nickel allergy?
